Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Analysts

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has been given an average rating of “Moderate Buy” by the five ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $7.40.

A number of research analysts recently issued reports on the stock. Stephens reissued an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday.

Actinium Pharmaceuticals Trading Up 4.3 %

Shares of ATNM opened at $1.20 on Tuesday. The firm’s 50-day moving average price is $1.21 and its 200-day moving average price is $1.48. The firm has a market capitalization of $37.44 million, a price-to-earnings ratio of -0.86 and a beta of 0.10. Actinium Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $10.24.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new stake in Actinium Pharmaceuticals during the third quarter valued at approximately $322,000. Wellington Management Group LLP purchased a new stake in shares of Actinium Pharmaceuticals in the third quarter worth $112,000. XTX Topco Ltd bought a new stake in shares of Actinium Pharmaceuticals during the 3rd quarter valued at $268,000. Barclays PLC lifted its stake in shares of Actinium Pharmaceuticals by 323.0% during the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after buying an additional 32,784 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Actinium Pharmaceuticals by 3.0% in the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after acquiring an additional 19,843 shares in the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).